New insights into circulating FABP4: Interaction with cytokeratin 1 on endothelial cell membranes

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1853, Issue 11, 2015, Pages 2966-2974

  Saavedra, Paula ^a   Girona, Josefa ^a   Bosquet, Alba ^a   Guaita, Sandra ^a   Canela, Núria ^a   Aragonès, Gemma ^a   Heras, Mercedes ^a   Masana, Lluís ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

Cell surface receptor; Cytokeratin 1; Endothelial cell; FABP4; FABP4 inhibition

Indexed keywords

CYTOKERATIN 1; FATTY ACID BINDING PROTEIN 4; FABP4 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN; KERATIN; MULTIPROTEIN COMPLEX;

ARTICLE; CONTROLLED STUDY; CROSS LINKING; CYTOPLASM; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE TEST; MASS SPECTROMETRY; MEMBRANE MICROPARTICLE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEOMICS; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; CELL MEMBRANE; CELL NUCLEUS; CYTOLOGY; GENETICS; METABOLISM; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MEMBRANE; CELL NUCLEUS; FATTY ACID-BINDING PROTEINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; KERATINS; MULTIPROTEIN COMPLEXES;

EID: 84941628343     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2015.09.002     Document Type: Article

References (51)

1. Zimmerman A.W., Veerkamp J.H. New insights into the structure and function of fatty acid-binding proteins. Cell. Mol. Life Sci. 2002, 59:1096-1116.
2. Hertzel A.V., Bernlohr D.A. The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function. Trends Endocrinol. Metab. 2000, 11:175-180.
3. Bernlohr D.A., Simpson M.A., Hertzel A.V., Banaszak L.J. Intracellular lipid-binding proteins and their genes. Annu. Rev. Nutr. 1997, 17:277-303.
4. Haunerland N.H., Spener F. Fatty acid-binding proteins-insights from genetic manipulations. Prog. Lipid Res. 2004, 43:328-349.
5. Makowski L., Hotamisligil G.S. The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. Curr. Opin. Lipidol. 2005, 16:543-548.
6. Wolfrum C. Cytoplasmic fatty acid binding protein sensing fatty acids for peroxisome proliferator activated receptor activation. Cell. Mol. Life Sci. 2007, 64:2465-2476.
7. Jenkins-Kruchten A.E., Bennaars-Eiden A., Ross J.R., Shen W.J., Kraemer F.B., Bernlohr D.A. Fatty acid-binding protein-hormone-sensitive lipase interaction. Fatty acid dependence on binding. J. Biol. Chem. 2003, 278:47636-47643.
8. Thompson B.R., Mazurkiewicz-Munoz A.M., Suttles J., Carter-Su C., Bernlohr D.A. Interaction of adipocyte fatty acid-binding protein (AFABP) and JAK2: AFABP/aP2 as a regulator of JAK2 signaling. J. Biol. Chem. 2009, 284:13473-13480.
9. Elmasri H., Karaaslan C., Teper Y., Ghelfi E., Weng M., Ince T.A., Kozakewich H., Bischoff J., Cataltepe S. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J. 2009, 23:3865-3873.
10. Furuhashi M., Fucho R., Gorgun C.Z., Tuncman G., Cao H., Hotamisligil G.S. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J. Clin. Invest. 2008, 118:2640-2650.
11. Hotamisligil G.S., Johnson R.S., Distel R.J., Ellis R., Papaioannou V.E., Spiegelman B.M. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996, 274:1377-1379.
12. Maeda K., Cao H., Kono K., Gorgun C.Z., Furuhashi M., Uysal K.T., Cao Q., Atsumi G., Malone H., Krishnan B., Minokoshi Y., Kahn B.B., Parker R.A., Hotamisligil G.S. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab. 2005, 1:107-119.
13. Scheja L., Makowski L., Uysal K.T., Wiesbrock S.M., Shimshek D.R., Meyers D.S., Morgan M., Parker R.A., Hotamisligil G.S. Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes 1999, 48:1987-1994.
14. Shum B.O., Mackay C.R., Gorgun C.Z., Frost M.J., Kumar R.K., Hotamisligil G.S., Rolph M.S. The adipocyte fatty acid-binding protein aP2 is required in allergic airway inflammation. J. Clin. Invest. 2006, 116:2183-2192.
15. Furuhashi M., Tuncman G., Gorgun C.Z., Makowski L., Atsumi G., Vaillancourt E., Kono K., Babaev V.R., Fazio S., Linton M.F., Sulsky R., Robl J.A., Parker R.A., Hotamisligil G.S. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007, 447:959-965.
16. Schlottmann I., Ehrhart-Bornstein M., Wabitsch M., Bornstein S.R., Lamounier-Zepter V. Calcium-dependent release of adipocyte fatty acid binding protein from human adipocytes. Int. J. Obes. 2014, 38:1221-1227.
17. Mita T., Furuhashi M., Hiramitsu S., Ishii J., Hoshina K., Ishimura S., Fuseya T., Watanabe Y., Tanaka M., Ohno K., Akasaka H., Ohnishi H., Yoshida H., Saitoh S., Shimamoto K., Miura T. FABP4 is secreted from adipocytes by adenyl cyclase-PKA- and guanylyl cyclase-PKG-dependent lipolytic mechanisms. Obesity (Silver Spring) 2014, 10.1002/oby.20954.
18. Erikci Ertunc M., Sikkeland J., Fenaroli F., Griffiths G., Daniels M.P., Cao H., Saatcioglu F., Hotamisligil G.S. Secretion of fatty acid binding protein aP2 from adipocytes through a non-classical pathway in response to adipocyte lipase activity. J. Lipid Res. 2014, 423-434.
19. Cabre A., Lazaro I., Cofan M., Jarauta E., Plana N., Garcia-Otin A.L., Ascaso J.F., Ferre R., Civeira F., Ros E., Masana L. FABP4 plasma levels are increased in familial combined hyperlipidemia. J. Lipid Res. 2010, 51:1173-1178.
20. Cabre A., Lazaro I., Girona J., Manzanares J.M., Marimon F., Plana N., Heras M., Masana L. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis 2007, 195:e150-e158.
21. Cabre A., Lazaro I., Girona J., Manzanares J.M., Marimon F., Plana N., Heras M., Masana L. Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria. Clin. Chem. 2008, 54:181-187.
22. Cabre A., Lazaro I., Girona J., Manzanares J.M., Marimon F., Plana N., Heras M., Masana L. Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. J. Lipid Res. 2008, 49:1746-1751.
23. Coll B., Cabre A., Alonso-Villaverde C., Lazaro I., Aragones G., Parra S., Girona J., Masana L. The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. Atherosclerosis 2008, 199:147-153.
24. Stejskal D., Karpisek M. Adipocyte fatty acid binding protein in a caucasian population: a new marker of metabolic syndrome?. Eur. J. Clin. Investig. 2006, 36:621-625.
25. Xu A., Wang Y., Xu J.Y., Stejskal D., Tam S., Zhang J., Wat N.M., Wong W.K., Lam K.S. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin. Chem. 2006, 52:405-413.
26. Tso A.W., Xu A., Sham P.C., Wat N.M., Wang Y., Fong C.H., Cheung B.M., Janus E.D., Lam K.S. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care 2007, 30:2667-2672.
27. Xu A., Tso A.W., Cheung B.M., Wang Y., Wat N.M., Fong C.H., Yeung D.C., Janus E.D., Sham P.C., Lam K.S. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007, 115:1537-1543.
28. Yeung D.C., Xu A., Cheung C.W., Wat N.M., Yau M.H., Fong C.H., Chau M.T., Lam K.S. Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1796-1802.
29. Aragones G., Ferre R., Lazaro I., Cabre A., Plana N., Merino J., Heras M., Girona J., Masana L. Fatty acid-binding protein 4 is associated with endothelial dysfunction in patients with type 2 diabetes. Atherosclerosis 2010, 213:329-331.
30. Agardh H.E., Folkersen L., Ekstrand J., Marcus D., Swedenborg J., Hedin U., Gabrielsen A., Paulsson-Berne G. Expression of fatty acid-binding protein 4/aP2 is correlated with plaque instability in carotid atherosclerosis. J. Intern. Med. 2011, 269:200-210.
31. Peeters W., de Kleijn D.P., Vink A., van de Weg S., Schoneveld A.H., Sze S.K., van der Spek P.J., de Vries J.P., Moll F.L., Pasterkamp G. Adipocyte fatty acid binding protein in atherosclerotic plaques is associated with local vulnerability and is predictive for the occurrence of adverse cardiovascular events. Eur. Heart J. 2011, 32:1758-1768.
32. Lamounier-Zepter V., Look C., Alvarez J., Christ T., Ravens U., Schunck W.H., Ehrhart-Bornstein M., Bornstein S.R., Morano I. Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ. Res. 2009, 105:326-334.
33. Aragones G., Saavedra P., Heras M., Cabre A., Girona J., Masana L. Fatty acid-binding protein 4 impairs the insulin-dependent nitric oxide pathway in vascular endothelial cells. Cardiovasc. Diabetol. 2012, 11:72.
34. Girona J., Rosales R., Plana N., Saavedra P., Masana L., Vallve J.C. FABP4 induces vascular smooth muscle cell proliferation and migration through a MAPK-dependent pathway. PLoS One 2013, 8.
35. Glass R., Loesch A., Bodin P., Burnstock G. P2X4 and P2X6 receptors associate with VE-cadherin in human endothelial cells. Cell. Mol. Life Sci. 2002, 59:870-881.
36. Klockenbusch C., Kast J. Optimization of formaldehyde cross-linking for protein interaction analysis of non-tagged integrin beta1. J. Biomed. Biotechnol. 2010, 2010:927585.
37. Vasilescu J., Guo X., Kast J. Identification of protein-protein interactions using in vivo cross-linking and mass spectrometry. Proteomics 2004, 4:3845-3854.
38. Shevchenko A., Wilm M., Vorm O., Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 1996, 68:850-858.
39. Gillilan R.E., Ayers S.D., Noy N. Structural basis for activation of fatty acid-binding protein 4. J. Mol. Biol. 2007, 372:1246-1260.
40. Astern J.M., Pendergraft W.F., Falk R.J., Jennette J.C., Schmaier A.H., Mahdi F., Preston G.A. Myeloperoxidase interacts with endothelial cell-surface cytokeratin 1 and modulates bradykinin production by the plasma kallikrein-kinin system. Am. J. Pathol. 2007, 171:349-360.
41. Uehara H., Takahashi T., Oha M., Ogawa H., Izumi K. Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progression. Int. J. Cancer 2014, 2558-2568.
42. Hui X., Li H., Zhou Z., Lam K.S., Xiao Y., Wu D., Ding K., Wang Y., Vanhoutte P.M., Xu A. Adipocyte fatty acid-binding protein modulates inflammatory responses in macrophages through a positive feedback loop involving c-Jun NH2-terminal kinases and activator protein-1. J. Biol. Chem. 2010, 285:10273-10280.
43. Lin W., Huang X., Zhang L., Chen D., Wang D., Peng Q., Xu L., Li J., Liu X., Li K., Ding K., Jin S., Li J., Wu D. BMS309403 stimulates glucose uptake in myotubes through activation of AMP-activated protein kinase. PLoS One 2012, 7.
44. Lee M.Y., Li H., Xiao Y., Zhou Z., Xu A., Vanhoutte P.M. Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells. Br. J. Pharmacol. 2011, 162:1564-1576.
45. Hasan A.A., Zisman T., Schmaier A.H. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:3615-3620.
46. Shariat-Madar Z., Schmaier A.H. Kininogen-cytokeratin 1 interactions in endothelial cell biology. Trends Cardiovasc. Med. 1999, 9:238-244.
47. Mahdi F., Shariat-Madar Z., Todd R.F., Figueroa C.D., Schmaier A.H. Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. Blood 2001, 97:2342-2350.
48. Mahdi F., Madar Z.S., Figueroa C.D., Schmaier A.H. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood 2002, 99:3585-3596.
49. Collard C.D., Montalto M.C., Reenstra W.R., Buras J.A., Stahl G.L. Endothelial oxidative stress activates the lectin complement pathway: role of cytokeratin 1. Am. J. Pathol. 2001, 159:1045-1054.
50. Polimeni L., Del Ben M., Baratta F., Perri L., Albanese F., Pastori D., Violi F., Angelico F. Oxidative stress: new insights on the association of non-alcoholic fatty liver disease and atherosclerosis. World J. Hepatol. 2015, 7:1325-1336.
51. Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J. Diabetes 2015, 6:456-480.